Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-DOTA-TP
- Development stage
- Preclinical
- Lead developer
- Xijing Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
68Ga-DOTA-TP is a gallium-68 labeled radiopharmaceutical diagnostic imaging agent developed by Xijing Hospital. It consists of a dual cyclic peptide analogue, DOTA-TP (DOTA-GGG-cyclo(CFDARGNFC)-GGG-cyclo(CFDARGNFC)), which specifically targets Desmoglein-2 (DSG2), a transmembrane glycoprotein overexpressed in various tumor cells. 68Ga-DOTA-TP is designed as a positron emission tomography (PET) tracer for tumor imaging and theranostics, demonstrating high tumor uptake and favorable target-to-nontarget ratios in preclinical models.
- Other names
- DOTA-GGG-cyclo(CFDARGNFC)-GGG-cyclo(CFDARGNFC)
02
Targets
DSG2 (Desmoglein-2)
Beyond the preview
Go deeper on 68Ga-DOTA-TP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-DOTA-TP.